From a candlestick perspective, AMD's recent price action shows clear signs of steady accumulation. Buyers are in control. The recent breakout in the stock suggests that momentum is building, but it remains fundamentally discounted. Taking a look at what could be fueling this sentiment shift beneath the surface - factors like ROCm traction, steady GPU traction with products like the MI300 and MI325X, hyperscaler relationships, and AMD's multi-year roadmap.

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study evaluating the Company's lead candidate, IMNN-001, for the treatment of women with newly diagnosed advanced ovarian cancer.

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at the Canaccord Genuity 45th Annual Growth Conference, being held on August 12-14, 2025 in Boston, MA.

Apple analysts are starting to wonder how much time the company has to find an AI strategy before consumers rethink their iPhone purchases. OpenAI's May acquisition of Jony Ive's startup IO for $6.5 billion put added pressure on Apple.

Boeing said it will further delay the launch of two new 737 Max variants to 2026. The delays come as the planemaker wrestles with a potential issue regarding the plane's deicing.

Positive ratings, muted returns; Thirteen straight Buy calls and a 5% yield haven't kept Portland from lagging large-load peers like Pinnacle West, OGE Energy, and Evergy. Volume isn't margin. Yes Oregon's tech and data center surge is boosting volume, but industrial rate structures mean profits don't move in step with demand. Balancing growth and capital needs; A $4.5B buildout and BBB+ credit rating put the focus on how Portland funds expansion without diluting returns.

Press Release 30 July 2025 HSBC CONTINENTAL EUROPE INTERIM RESULTS 2025 On 29 July 2025, HSBC Continental Europe's Board of Directors approved the consolidated financial statements for the first half of 2025. Performance during the first half of 2025 reflected strong revenue growth in Corporate and Institutional Banking1 driven by increased client activity.

AVENTURA, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a leader in artificial intelligence (AI)-powered defense and security solutions, today announced that it has been selected by the U.S. Army to participate in the Army Futures Command's (AFC) Concept Focused Warfighting Experiment (CFWE) Maneuver (CFWE-M) 2026 event being held at Fort Benning, Georgia in March through April 2026.

Stockholders Are Reminded That the Heliogen, Inc. Special Meeting of Stockholders Will Be Held Virtually on Friday, August 8, 2025, at 6:00 a.m. Pacific Time (9:00 a.m.

Tesla and Samsung have just announced a partnership centered around a multibillion-dollar chip supply agreement.

The maker of Ozempic and Wegovy just had its worst day since Black Monday 1987

The plan to spin off joint venture Virgin Media O2's fixed network in Britain had been scrapped, Telefonica's Chief Executive Marc Murtra told Reuters on Wednesday.

Etsy beat Wall Street expectations for second-quarter revenue on Wednesday, helped by strong demand for handcrafted goods and personalized gifts sold at the online marketplace, sending the company's shares up about 3% in premarket trading.

Partnership combines Cognizant's deep industry and domain expertise and WRITER's end-to-end agentic platform to help enterprises deploy secure, specialized AI agents at scale. TEANECK, N.J.

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the value of early intervention and supports a limited duration dosing approach with sustained long-term benefits INDIANAPOLIS , July 30, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study showing that participants treated with Kisunla (donanemab-azbt) demonstrated slowing of decline, a benefit that continued to grow over three years compared to an untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI).1 …

BUFFALO, N.Y. , July 30, 2025 /PRNewswire/ -- KeyBank (NYSE: KEY) and the Buffalo Sabres today announced a 10-year extension of their arena naming rights deal.

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.

Kohl's was amongst a new wave of meme stocks that surged from traders taking advantage of cheap share prices and heavy short positions.

Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75 Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and T-VASI at 3% Concentration Company Will Terminate Extension Phase of Trial and Seek External Partner for Continued Development of Repibresib BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced topline results from its Phase 2b trial evaluating Repibresib …

HAMILTON, Bermuda , July 30, 2025 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and six months ended June 30, 2025. Highlights and Recent Activity Reported Adjusted earnings and net income attributable to common stockholders of $9.0 million for the three months ended June 30, 2025, or $0.22 earnings per basic and diluted share, compared to Adjusted earnings of $47.6 million and net income attributable to common stockholders of $61.8 million, or $1.14 Adjusted earnings per basic share and $1.13 Adjusted earnings per diluted share for the three months ended …